glaucoma 1, open angle, A

disease
On this page

Also known as glaucoma 1, open angle, type Aglaucoma 1A, primary open angleglaucoma hereditary, juvenileGLC1AJOAG1JOAG1Ajuvenile glaucoma caused by mutation in MYOCjuvenile open angle glaucoma caused by mutation in MYOCMYOC juvenile glaucomaMYOC juvenile open angle glaucomaprimary open angle glaucoma juvenile onset 1

Summary

glaucoma 1, open angle, A (MONDO:0007664) is a disease caused by MYOC (GenCC Definitive), with 1 cohort gene.

At a glance

  • Causal gene: MYOC (GenCC Definitive)
  • Cohort genes: 1
  • ClinVar variants: 77

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameglaucoma 1, open angle, A
Mondo IDMONDO:0007664
MeSHC564234
OMIM137750
UMLSC1842028
MedGen333974
GARD0009485
Is cancer (heuristic)no

Also known as: glaucoma 1, open angle, A · glaucoma 1, open angle, type A · glaucoma 1A, primary open angle · glaucoma hereditary, juvenile · GLC1A · JOAG1 · JOAG1A · juvenile glaucoma caused by mutation in MYOC · juvenile open angle glaucoma caused by mutation in MYOC · MYOC juvenile glaucoma · MYOC juvenile open angle glaucoma · primary open angle glaucoma juvenile onset 1

Data availability: 77 ClinVar variants · 4 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by body system or component › disorder of orbital regioneye disorderglaucomaopen-angle glaucomajuvenile open angle glaucomaglaucoma 1, open angle, A

Related subtypes (5): glaucoma 1, open angle, J, glaucoma 1, open angle, K, glaucoma 1, open angle, M, glaucoma 1, open angle, N, glaucoma 1, open angle, l

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

77 retrieved; paginated sample, class counts are floors:

33 uncertain significance, 16 likely benign, 12 benign, 10 pathogenic, 6 likely pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
1342202NM_000261.2(MYOC):c.1130C>T (p.Thr377Met)MYOCPathogenicreviewed by expert panel
7946NM_000261.2(MYOC):c.1309T>C (p.Tyr437His)MYOCPathogenicreviewed by expert panel
7947NM_000261.2(MYOC):c.1091G>T (p.Gly364Val)MYOCPathogenicreviewed by expert panel
7948NM_000261.2(MYOC):c.1109C>T (p.Pro370Leu)MYOCPathogenicreviewed by expert panel
7949NM_000261.2(MYOC):c.1102C>T (p.Gln368Ter)MYOCPathogenicreviewed by expert panel
7951NM_000261.2(MYOC):c.1440C>A (p.Asn480Lys)MYOCPathogenicreviewed by expert panel
7952NM_000261.2(MYOC):c.1099G>A (p.Gly367Arg)MYOCPathogenicreviewed by expert panel
7954NM_000261.2(MYOC):c.1267A>G (p.Lys423Glu)MYOCPathogenicreviewed by expert panel
7956NM_000261.2(MYOC):c.1297T>C (p.Cys433Arg)MYOCPathogenicreviewed by expert panel
7960NM_000261.2(MYOC):c.754G>A (p.Gly252Arg)MYOCPathogenicreviewed by expert panel
1173106NM_000261.2(MYOC):c.1435T>C (p.Tyr479His)MYOCLikely pathogenicreviewed by expert panel
1686792NM_000261.2(MYOC):c.1495A>T (p.Ile499Phe)MYOCLikely pathogenicreviewed by expert panel
30205NM_000261.2(MYOC):c.1430T>A (p.Ile477Asn)MYOCLikely pathogenicreviewed by expert panel
625855NM_000261.2(MYOC):c.1153G>A (p.Glu385Lys)MYOCLikely pathogenicreviewed by expert panel
7950NM_000261.2(MYOC):c.1430T>G (p.Ile477Ser)MYOCLikely pathogenicreviewed by expert panel
7961NM_000261.2(MYOC):c.1138G>C (p.Asp380His)MYOCLikely pathogenicreviewed by expert panel
1324770NM_000261.2(MYOC):c.604+1G>CMYOCUncertain significancereviewed by expert panel
1324771NM_000261.2(MYOC):c.898G>T (p.Glu300Ter)MYOCUncertain significancereviewed by expert panel
1686781NM_000261.2(MYOC):c.271C>T (p.Arg91Ter)MYOCUncertain significancereviewed by expert panel
1698724NM_000261.2(MYOC):c.526del (p.Glu176fs)MYOCUncertain significancereviewed by expert panel
1698736NM_000261.2(MYOC):c.844del (p.Gln282fs)MYOCUncertain significancereviewed by expert panel
1698837NM_000261.2(MYOC):c.1288T>C (p.Phe430Leu)MYOCUncertain significancereviewed by expert panel
1803197NM_000261.2(MYOC):c.1349A>G (p.Asn450Ser)MYOCUncertain significancereviewed by expert panel
1930166NM_000261.2(MYOC):c.472C>T (p.Arg158Ter)MYOCUncertain significancereviewed by expert panel
2671648NM_000261.2(MYOC):c.358del (p.Glu120fs)MYOCUncertain significancereviewed by expert panel
293702NM_000261.2(MYOC):c.*426C>TMYOCUncertain significancecriteria provided, single submitter
293703NM_000261.2(MYOC):c.*331A>GMYOCUncertain significancecriteria provided, single submitter
293704NM_000261.2(MYOC):c.*241A>GMYOCUncertain significancecriteria provided, multiple submitters, no conflicts
293705NM_000261.2(MYOC):c.*188C>TMYOCUncertain significancecriteria provided, single submitter
293706NM_000261.2(MYOC):c.*182C>AMYOCUncertain significancecriteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 7 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
MYOCDefinitiveAutosomal dominantglaucoma 1, open angle, A7

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
MYOCOrphanet:98976Congenital glaucoma
MYOCOrphanet:98977Juvenile glaucoma

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
MYOCHGNC:7610ENSG00000034971Q99972Myocilingencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
MYOCMyocilinSecreted glycoprotein regulating the activation of different signaling pathways in adjacent cells to control different processes including cell adhesion, cell-matrix adhesion, cytoskeleton organization and cell migration.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Other/Unknown11.8×0.558

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
MYOCOther/UnknownnoOlfac-like_dom, Olfactomedin-like_domain

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
calcaneal tendon1
esophagogastric junction muscularis propria1
mucosa of stomach1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
MYOC201tissue_specificmarkercalcaneal tendon, mucosa of stomach, esophagogastric junction muscularis propria

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
MYOC1,272

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
MYOCQ9997224

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 0. Enrichment computed across 1 evidence-associated genes (0 with Reactome annotation).

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
skeletal muscle hypertrophy116852.0×0.001MYOC
clustering of voltage-gated sodium channels12407.4×0.003MYOC
ERBB2-ERBB3 signaling pathway11685.2×0.003MYOC
positive regulation of mitochondrial depolarization11685.2×0.003MYOC
negative regulation of cell-matrix adhesion1887.0×0.003MYOC
myelination in peripheral nervous system1887.0×0.003MYOC
negative regulation of Rho protein signal transduction1766.0×0.003MYOC
positive regulation of focal adhesion assembly1648.1×0.003MYOC
non-canonical Wnt signaling pathway1581.1×0.003MYOC
negative regulation of stress fiber assembly1581.1×0.003MYOC
regulation of MAPK cascade1455.5×0.004MYOC
positive regulation of substrate adhesion-dependent cell spreading1374.5×0.004MYOC
positive regulation of stress fiber assembly1312.1×0.005MYOC
bone development1276.3×0.005MYOC
positive regulation of JNK cascade1163.6×0.008MYOC
neuron projection development1122.1×0.010MYOC
osteoblast differentiation1121.2×0.010MYOC
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction178.4×0.014MYOC
positive regulation of cell migration161.7×0.017MYOC
signal transduction116.1×0.062MYOC

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
MYOC00

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
MYOC4Binding:4

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1MYOC

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
MYOC4

Clinical trials & evidence

Clinical trials

Clinical trials: 0.